Better Health for All

Denali Therapeutics Inc. develops drug candidates aimed at treating neurodegenerative diseases such as MPS II, Parkinson's, Frontotemporal Dementia, MPS IIIA, MPS I, and systemic inflammation.

As these are drug candidates in development and not yet approved or marketed products, the company's current goods or services have no significant positive or negative health impact on patients.

Fair Pay & Worker Respect

For fiscal year 2024, the CEO pay ratio was 19:1.

The company has reported zero reportable regulatory safety incidents since operations commenced in 2015. Denali Therapeutics offers employer-funded health insurance, with one employee review stating 100% premium coverage for the employee.

Honest & Fair Business

Eight out of ten current directors, representing 80% of the board, are determined to be independent according to Nasdaq rules and Canadian securities laws.

The company has a written whistleblower policy that includes a hotline and anonymous reporting options, with the Audit Committee responsible for establishing and overseeing related procedures. A Clawback Policy is in place that addresses accounting restatements due to material noncompliance with financial reporting requirements, indicating that restatements occur every 2-3 years. The Audit Committee oversees the corporate accounting and financial reporting process and the work of independent auditors, and the organization obtains separate, independent audited financial statements. A Code of Business Conduct and Ethics has been adopted, which includes compliance with the Foreign Corrupt Practices Act of 1977 and similar anti-corruption legislation, with the Chief Legal Officer overseeing compliance.

Kind to Animals

Denali Therapeutics Inc. conducts in vivo experiments using various animal models, including mice and cynomolgus monkeys.

All animal procedures adhere to ethical regulations and protocols approved by Denali Therapeutics Institutional Animal Care and Use Committee. The company utilizes in vitro cell cultures for characterization and cell binding/trafficking assays, indicating some use of non-animal methods, but research relies heavily on in vivo animal models. The studies mention using 15,000–25,000 animals per year. Mice are housed under a 12-hour light/dark cycle with ad libitum access to water and standard rodent diet, and group-housed up to five sex-matched animals per cage when possible. Humane endpoints for euthanasia include body weight loss of ≥10%, hindlimb paralysis, or inability to right itself within 20 seconds. The company uses bacon-flavored grain-based rodent diet for some studies. The company's R&D focuses on developing novel small-molecule activators and brain delivery technologies, but there is no explicit mention of investment in animal-free technologies, suggesting less than 1% of R&D spending supports such development.

Safe & Smart Tech

Users can opt-out of receiving non-service emails, with unsubscribe instructions provided in the Privacy Policy.

This indicates basic data control options with significant limitations, as no other controls over personal data or privacy settings are detailed. The company's Form 10-K filings and Code of Business Conduct and Ethics indicate compliance with relevant U.S. securities regulations, FDA regulations, the Foreign Corrupt Practices Act, and export controls. Its Privacy Policy also states compliance with applicable laws and regulations. No specific regulatory actions, violations, fines, or compliance issues are mentioned for Denali Therapeutics Inc. (DNLI.US).